A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2010 Mar; 87(3):303-10.